Cagrilintide

1.Overview

Cagrilintide is a synthetic, long-acting analogue of amylin, a hormone co-secreted with insulin by pancreatic beta cells. Unlike native amylin, which has a short half-life, cagrilintide is engineered for extended duration of action, allowing for once-weekly administration. It is currently under investigation as a therapeutic agent for the management of obesity and type 2 diabetes.

Research into cagrilintide has expanded from monotherapy dose-finding studies to combination regimens, most notably with the GLP-1 receptor agonist semaglutide. This combination approach aims to leverage complementary pathways to achieve greater efficacy in weight reduction and glycemic control than either agent might provide alone.

2.Mechanism of Action

Cagrilintide acts as a dual amylin and calcitonin receptor agonist (DACRA). It binds to the calcitonin receptor (CTR) when it is complexed with receptor activity-modifying proteins (RAMPs). Specifically, it targets the AMY1 and AMY3 receptor subtypes, which are expressed in brain regions associated with the regulation of energy balance and satiety.

By activating these receptors, cagrilintide mimics the physiological effects of endogenous amylin, which include the slowing of gastric emptying and the promotion of satiety. Preclinical research using RAMP1/3 knockout models has confirmed that these specific receptor complexes are essential for the weight-lowering effects observed with cagrilintide administration.

3.Why Researchers Study It

Current research interest is heavily focused on the therapeutic potential of cagrilintide in the context of metabolic syndrome. Investigators are evaluating its efficacy in reducing body weight, improving glycemic control, and addressing cardiometabolic risk factors in patients with obesity and type 2 diabetes.

A significant portion of ongoing research is dedicated to the 'CagriSema' combination therapy. By pairing an amylin analogue with a GLP-1 receptor agonist, researchers aim to determine if the dual-pathway approach provides superior outcomes in weight loss and metabolic stabilization compared to existing standard-of-care treatments.

4.Pharmacology & Molecular Identity

Cagrilintide is an acylated peptide, a modification that extends its half-life and enables once-weekly subcutaneous dosing. It exhibits high structural homology to human amylin but possesses increased stability and potency at the target receptor complexes.

Pharmacologically, it is classified as a DACRA. While its primary action is through the AMY receptors, its interaction with the calcitonin receptor is a defining feature of its pharmacology. The exact contribution of the calcitonin receptor versus the amylin receptor to the overall clinical profile remains a subject of ongoing scientific investigation.

5.Human Research Evidence

Human evidence for cagrilintide is derived from several multicenter, randomized, double-blind clinical trials. Phase 2 dose-finding studies established that cagrilintide produces dose-dependent weight loss in individuals with overweight or obesity. These trials also provided initial data on safety and tolerability, noting that gastrointestinal side effects are common, similar to other agents in the incretin/amylin class.

More recent phase 3 data has further characterized the efficacy of cagrilintide, particularly in combination with semaglutide. Studies have shown that this combination leads to significant reductions in body weight and improvements in HbA1c levels in patients with type 2 diabetes and obesity compared to placebo, supporting its continued development in large-scale clinical programs.

6.Preclinical Research

Preclinical studies have been instrumental in identifying the specific receptor pathways through which cagrilintide exerts its effects. Research in mice has demonstrated that cagrilintide reduces food intake and body weight, with these effects being abolished in RAMP1/3 knockout models, confirming the necessity of the AMY1 and AMY3 receptors.

These studies have also helped characterize the dose-response relationship and the stability of the molecule in vivo. The preclinical data provides a mechanistic foundation for the clinical observations of satiety and weight loss, distinguishing the amylin-based mechanism from other metabolic therapies.

7.Safety & Research Limitations

Clinical trials have identified gastrointestinal adverse events, such as nausea, as the most frequently reported side effects associated with cagrilintide, which is consistent with the profile of other amylin-based therapies. These effects are generally described as mild to moderate and often transient.

Limitations in the current evidence include the need for longer-term data to fully understand the safety profile, particularly regarding potential rare or delayed adverse events. As an investigational agent, the full spectrum of its safety, including long-term cardiovascular and metabolic outcomes, continues to be evaluated in ongoing phase 3 clinical programs.

8.Evidence Quality & Research Gaps

Despite promising clinical results, several research gaps remain. There is a need for more comprehensive data on the long-term durability of weight loss and the maintenance of metabolic improvements after treatment cessation. Additionally, the comparative effectiveness of cagrilintide monotherapy versus combination therapies across diverse patient populations requires further study.

Future research is also expected to explore the potential for non-peptide or oral small-molecule alternatives to the current injectable peptide formulation. Understanding the full range of multisystem benefits, beyond weight loss, remains a priority for the scientific community to better define the role of amylin analogues in chronic disease management.

9.Frequently Asked Questions

10.References

1. 1.Rubio-Herrera MA, Mera-Carreiro S. Weight management treatment in obesity. Medicina clinica. 2025 Nov. DOI: 10.1016/j.medcli.2025.107152.PMID: 40865172
2. 2.Garvey WT, Blüher M, Osorto Contreras CK, Davies MJ, Winning Lehmann E. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. The New England journal of medicine. 2025 Aug 14. DOI: 10.1056/NEJMoa2502081.PMID: 40544433
3. 3.Yao H, Zhang A, Li D, Wu Y, Wang CZ. Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis. BMJ (Clinical research ed.). 2024 Jan 29. DOI: 10.1136/bmj-2023-076410.PMID: 38286487
4. 4.Madsbad S, Holst JJ. The promise of glucagon-like peptide 1 receptor agonists (GLP-1RA) for the treatment of obesity: a look at phase 2 and 3 pipelines. Expert opinion on investigational drugs. 2025 Mar. DOI: 10.1080/13543784.2025.2472408.PMID: 40022548
5. 5.Davies MJ, Bajaj HS, Broholm C, Eliasen A, Garvey WT. Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes. The New England journal of medicine. 2025 Aug 14. DOI: 10.1056/NEJMoa2502082.PMID: 40544432
6. 6.Savas M, Kuckuck S, Boon MR, van Rossum EFC. Beyond weight loss: multisystem benefits of obesity medications. The lancet. Diabetes & endocrinology. 2026 Aug. DOI: 10.1016/S2213-8587(26)00100-2.PMID: 42208956
7. 7.Frias JP, Deenadayalan S, Erichsen L, Knop FK, Lingvay I. Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial. Lancet (London, England). 2023 Aug 26. DOI: 10.1016/S0140-6736(23)01163-7.PMID: 37364590
8. 8.Lau DCW, Erichsen L, Francisco AM, Satylganova A, le Roux CW. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. Lancet (London, England). 2021 Dec 11. DOI: 10.1016/S0140-6736(21)01751-7.PMID: 34798060
9. 9.Panou T, Gouveri E, Popovic DS, Papanas N. Amylin analogs for the treatment of obesity without diabetes: present and future. Expert review of clinical pharmacology. 2024 Sep 30. DOI: 10.1080/17512433.2024.2409403.PMID: 39317404
10. 10.D'Ascanio AM, Mullally JA, Frishman WH. Cagrilintide: A Long-Acting Amylin Analog for the Treatment of Obesity. Cardiology in review. 2024 Jan-Feb 01. DOI: 10.1097/CRD.0000000000000513.PMID: 36883831